Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

BACKGROUND: Patients with chronic lymphocytic leukaemia (CLL) with TP53 aberrations respond poorly to first-line chemoimmunotherapy resulting in early relapse and short survival. We investigated the safety and activity of ibrutinib in previously untreated and relapsed or refractory CLL with TP53 abe...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Lancet Oncol
Main Authors: Farooqui, Mohammed Z H, Valdez, Janet, Martyr, Sabrina, Aue, Georg, Saba, Nakhle, Niemann, Carsten U, Herman, Sarah E M, Tian, Xin, Marti, Gerald, Soto, Susan, Hughes, Thomas E, Jones, Jade, Lipsky, Andrew, Pittaluga, Stefania, Stetler-Stevenson, Maryalice, Yuan, Constance, Lee, Yuh Shan, Pedersen, Lone B, Geisler, Christian H, Calvo, Katherine R, Arthur, Diane C, Maric, Irina, Childs, Richard, Young, Neal S, Wiestner, Adrian
Format: Artigo
Sprog:Inglês
Udgivet: 2014
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4342187/
https://ncbi.nlm.nih.gov/pubmed/25555420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(14)71182-9
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker